BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

China flag China · Delayed Price · Currency is CNY
59.80
+0.36 (0.61%)
At close: Sep 30, 2025
0.61%
Market Cap25.26B
Revenue (ttm)1.16B
Net Income (ttm)99.98M
Shares Out422.40M
EPS (ttm)0.24
PE Ratio252.60
Forward PE96.45
Dividend0.10 (0.16%)
Ex-Dividend DateJun 23, 2025
Volume12,507,479
Average Volume15,466,124
Open61.50
Previous Close59.44
Day's Range59.77 - 61.90
52-Week Range28.45 - 122.59
Beta0.30
RSI22.20
Earnings DateOct 28, 2025

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., a pharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products in China. The company offers Eribulin mesylate injection, Voriconazole for injection, Entecavir tablets, Oseltamivir phosphate capsule and dry suspension, Agatroban injection, Mikafungin sodium for injection, Fondaparinux sodium injection, and Caspofungin acetate for injection. It also provides antitumor, antibodies drug conjugate, anti-infection, angiography, gynecology, c... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 1,151
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688166
Full Company Profile

Financial Performance

In 2024, SHA:688166's revenue was 1.28 billion, an increase of 8.74% compared to the previous year's 1.18 billion. Earnings were 189.17 million, a decrease of -6.57%.

Financial Statements

News

There is no news available yet.